BETHESDA, MD (Reuters Health) Jun 21 –
US Food and Drug Administration (FDA) advisers voted 16-2 on Friday to back approval of an over-the-counter (OTC) version of the heartburn medication Prilosec (omeprazole).
If the FDA follows its panel’s advice, which it usually does, the drug would be marketed by Procter & Gamble (P&G) as Prilosec 1. Developed by AstraZeneca, Prilosec lost its patent protection last October, and the company has been battling ever since to block generic rivals.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!